PMID- 33047263
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20211102
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Print)
IS  - 1523-3774 (Linking)
VI  - 22
IP  - 12
DP  - 2020 Oct 12
TI  - Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel 
      Vasculitis.
PG  - 85
LID - 10.1007/s11926-020-00961-0 [doi]
LID - 85
AB  - PURPOSE: While glucocorticoids (GCs) are effective in large vessel vasculitis 
      (LVV), they may cause serious adverse events (AEs), especially if taken for 
      longer durations and at higher doses. Unfortunately, patients suffering from LVV 
      often need long-term treatment with GCs; therefore, toxicity needs to be expected 
      and countered. RECENT FINDINGS: GCs remain the mainstay of therapy for both giant 
      cell arteritis and Takayasu arteritis. In order to minimize their toxicity, the 
      following strategies should be considered: GC tapering, administration of 
      conventional synthetic (e.g., methotrexate) or biologic (e.g., tocilizumab) 
      GC-sparing agents, as well as monitoring, prophylaxis, and treatment of 
      GC-related AEs. Several drugs are currently under investigation to expand the 
      armamentarium for the treatment of LVV. GC treatment in LVV is effective but 
      associated with toxicity. Strategies to minimize this toxicity should be applied 
      when treating patients suffering from LVV.
FAU - Palmowski, Andriko
AU  - Palmowski A
AD  - Department of Rheumatology and Clinical Immunology, Charite - 
      Universitatsmedizin, Berlin, Germany.
FAU - Buttgereit, Frank
AU  - Buttgereit F
AD  - Department of Rheumatology and Clinical Immunology, Charite - 
      Universitatsmedizin, Berlin, Germany. frank.buttgereit@charite.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201012
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Glucocorticoids)
RN  - I031V2H011 (tocilizumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Giant Cell Arteritis/drug therapy
MH  - *Glucocorticoids/adverse effects/therapeutic use
MH  - Humans
MH  - Methotrexate/therapeutic use
MH  - *Takayasu Arteritis/drug therapy
PMC - PMC7550368
OTO - NOTNLM
OT  - Adverse events
OT  - Giant cell arteritis
OT  - Glucocorticoids
OT  - Large vessel vasculitis
OT  - Prednisone
OT  - Steroids
OT  - Takayasu arteritis
COIS- AP has no conflicts of interest to disclose. FB reported receiving consultancy 
      fees, honoraria, and travel expenses from Roche, Sanofi, and Galapagos, and grant 
      support from Roche and Sanofi. He currently serves as principal investigator and 
      site investigator in a GCA trial (Sanofi).
EDAT- 2020/10/14 06:00
MHDA- 2021/11/03 06:00
PMCR- 2020/10/12
CRDT- 2020/10/13 05:40
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/13 05:40 [entrez]
PHST- 2020/10/14 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/10/12 00:00 [pmc-release]
AID - 10.1007/s11926-020-00961-0 [pii]
AID - 961 [pii]
AID - 10.1007/s11926-020-00961-0 [doi]
PST - epublish
SO  - Curr Rheumatol Rep. 2020 Oct 12;22(12):85. doi: 10.1007/s11926-020-00961-0.